Voyager Therapeutics
VYGR
81 hedge funds and large institutions have $184M invested in Voyager Therapeutics in 2023 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 28 increasing their positions, 16 reducing their positions, and 12 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
100% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 12
75% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 16
26% more capital invested
Capital invested by funds: $145M → $184M (+$38.3M)
16% more funds holding
Funds holding: 70 → 81 (+11)
7.14% less ownership
Funds ownership: 62.15% → 55.01% (-7.1%)
25% less call options, than puts
Call options by funds: $2.09M | Put options by funds: $2.77M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$7.03M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$6.34M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.45M |
| 4 |
Jane Street
New York
|
+$1.18M |
| 5 |
AC
Armistice Capital
New York
|
+$1.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TGI
TRV GP III
Boston,
Massachusetts
|
-$17.8M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$7.18M |
| 3 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$670K |
| 4 |
CANY
Caxton Associates (New York)
New York
|
-$558K |
| 5 |
HIM
Hillsdale Investment Management
Toronto,
Ontario, Canada
|
-$506K |
VYGR Hedge Fund Activity: Q1 2023 in Review
81 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Voyager Therapeutics (VYGR) for Q1 2023, worth a combined $184M — up 26% from $145M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new VYGR positions and 12 closed out — a net gain of 12 holders — while 28 added to existing stakes and 16 trimmed.
The largest buyer was Millennium Management, adding an estimated $7.03M. The largest seller was TRV GP III, cutting an estimated $17.8M.
- 81 institutional investors held Voyager Therapeutics (VYGR) as of Q1 2023, up from 70 in Q4 2022.
- Funds reported $184M of Voyager Therapeutics stock for Q1 2023, up 26% quarter-over-quarter.
- 24 funds opened new Voyager Therapeutics positions in Q1 2023 and 12 closed out, a net change of +12 holders.
- The largest Voyager Therapeutics buyer in Q1 2023 was Millennium Management, an estimated $7.03M added.
- The largest Voyager Therapeutics seller in Q1 2023 was TRV GP III, an estimated $17.8M sold.
Based on aggregated 13F filings for Q1 2023.